(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Non-Hodgkin Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.
Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.
- Non-Hodgkin Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment
- Emerging Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.
- In May 2023, The US FDA has granted approval for the investigational new drug (IND) application submitted by SIRPant Immuno therapeutics. This approval allows the commencement of a phase I clinical trial, marking the first time the treatment will be tested in humans, aimed at addressing relapsed refractory non-Hodgkin lymphoma.
- In May 2023, The US FDA has granted approval to AbbVie for EPKINLY (epcoritamab-bysp), a T-cell engaging bispecific antibody designed for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Non-Hodgkin Lymphoma Overview
A malignancy of the lymphatic system is called non-Hodgkin’s lymphoma (NHL). It happens when lymphocytes give rise to tumors. One variety of white blood cell is the lymphocyte. NHL is more prevalent than lymphoma Hodgkin’s. The presence of a particular kind of aberrant cell known as the Reed-Sternberg cell is the primary distinction between NHL and Hodgkin’s lymphoma.
Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight
Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
- AUTO4: Autolus
- GB226: Genor Biopharma
- Epcoritamab: AbbVie/ Genmab
- Capivasertib: AstraZeneca
- HRS-3738: Jiangsu Hengrui Medicine
- PCLX-001: Pacylex Pharmaceuticals
- ZN-d5: Zentera Therapeutics
- TC-110: TCR2 Therapeutics
- AB-101: Artiva Biotherapeutics
- LOXO-305: Loxo Oncology
- AB-205: Angiocrine Bioscience
- Venetoclax: AbbVie
- Tisagenlecleucel: Novartis
Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
- Non-Hodgkin Lymphoma Assessment by Product Type
- Non-Hodgkin Lymphoma By Stage and Product Type
- Non-Hodgkin Lymphoma Assessment by Route of Administration
- Non-Hodgkin Lymphoma By Stage and Route of Administration
- Non-Hodgkin Lymphoma Assessment by Molecule Type
- Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight’s Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies
Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:
Key Non-Hodgkin Lymphoma companies developing therapies for Non-Hodgkin Lymphoma are – AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.
Non-Hodgkin Lymphoma Pipeline Analysis:
The Non-Hodgkin Lymphoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
- Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies
Non-Hodgkin Lymphoma Pipeline Market Drivers
- Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.
Non-Hodgkin Lymphoma Pipeline Market Barriers
- However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.
Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight
- Coverage: Global
- Key Non-Hodgkin Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
- Key Non-Hodgkin Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
- Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
- Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. Non-Hodgkin Lymphoma Report Introduction
2. Non-Hodgkin Lymphoma Executive Summary
3. Non-Hodgkin Lymphoma Overview
4. Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Non-Hodgkin Lymphoma Pipeline Therapeutics
6. Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)
7. Non-Hodgkin Lymphoma Mid Stage Products (Phase II)
8. Non-Hodgkin Lymphoma Early Stage Products (Phase I)
9. Non-Hodgkin Lymphoma Preclinical Stage Products
10. Non-Hodgkin Lymphoma Therapeutics Assessment
11. Non-Hodgkin Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Hodgkin Lymphoma Key Companies
14. Non-Hodgkin Lymphoma Key Products
15. Non-Hodgkin Lymphoma Unmet Needs
16 . Non-Hodgkin Lymphoma Market Drivers and Barriers
17. Non-Hodgkin Lymphoma Future Perspectives and Conclusion
18. Non-Hodgkin Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting